Navigation Links
Architecture of signaling proteins enhances knowledge of key receptors
Date:6/22/2014

DURHAM, N.C. -- A team of scientists from Duke Medicine, the University of Michigan and Stanford University has determined the underlying architecture of a cellular signaling complex involved in the body's response to stimuli such as light and pain.

This complex, consisting of a human cell surface receptor and its regulatory protein, reveals a two-step mechanism that has been hypothesized previously but not directly documented.

The findings, reported on June 22, 2014, in the journal Nature, provide structural images of a G-protein coupled receptor (GPCR) in action.

"It is crucial to visualize how these receptors work to fully appreciate how our bodies respond to a wide array of stimuli, including light, hormones and various chemicals," said co-senior author Robert J. Lefkowitz, M.D., the James B. Duke Professor of Medicine at Duke University School of Medicine and Howard Hughes Medical Institute investigator.

Lefkowitz is co-senior author with Georgios Skiniotis, Ph.D., the Jack E. Dixon Collegiate Professor at the Life Sciences Institute at the University of Michigan, and Brian K. Kobilka, M.D., the Helene Irwin Fagan Chair in Cardiology at Stanford University School of Medicine. Lefkowitz and Kobilka shared the 2012 Nobel Prize in Chemistry for their discoveries involving GPCRs.

GPCRs represent the largest family of drug targets for human diseases, including cardiovascular disorders, neurological ailments and various types of cancer. The protein beta arrestin is key for regulating these receptors, and the authors have visualized a complex of the protein beta arrestin along with the receptor involved in the "fight-or-flight" response in humans.

"Arrestin's primary role is to put the cap on GPCR signaling. Elucidating the structure of this complex is crucial for understanding how the receptors are desensitized in order to prevent aberrant signaling," Skiniotis said.

"High-resoluti
'/>"/>

Contact: Rachel Harrison
rachel.harrison@duke.edu
919-684-4148
Duke University Medical Center
Source:Eurekalert  

Page: 1 2 3

Related biology news :

1. Cell division speed influences gene architecture
2. RNA shows potential as boiling-resistant anionic polymer material for nanoarchitectures
3. Lightweight construction materials of highest stability thanks to their microarchitecture
4. Plant cell architecture: Growth toward a light source
5. Complex genetic architectures: Some common symptoms of trisomy 21
6. NREL researchers use imaging technologies to solve puzzle of plant architecture
7. Architecture of rod sensory cilium disrupted by mutation
8. Is it a rock, or is it Jell-O? Defining the architecture of rhomboid enzymes
9. Herbivores select on floral architecture in a South African bird-pollinated plant
10. Stem cells found to play restorative role when affecting brain signaling process
11. Geniposide protects hippocampal neurons via the non-classical estrogen signaling pathway
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Architecture of signaling proteins enhances knowledge of key receptors
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you ... remember your password, site key or the answer to your secret ... Today, Hoyos Labs , a digital infrastructure ... an end to the frustration that comes with usernames, passwords and ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report to their ... The integration of biometrics and smart cards for ... driver,s license is one of the major trends witnessed ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... TORONTO For the second time in as many ... signed a licensing agreement with US-based Athena Diagnostics Inc. to ... developed by CAMH scientist Dr. John Vincent as well as ... their research into genetic causes of intellectual disability. The test ...
... Researchers at Rhode Island Hospital have discovered how cells ... findings shed new light on how the body repairs itself ... and offers hope for tissue regeneration. The paper is published ... Hematology and is now available online in advance of ...
... of type 2 diabetes places a huge burden on its ... of all heart attacks and stroke cases, but also many ... this metabolic syndrome. In Germany alone, some seven million people ... worldwide is projected to reach 370 million by the year ...
Cached Biology News:New genetic test for cause of intellectual disability to be launched 2Offering hope for tissue regeneration 2Offering hope for tissue regeneration 3The pig and its pancreas 2The pig and its pancreas 3
(Date:1/22/2015)...  Transwestern | RBJ today announces the firm brokered a long-term ... a leading biopharmaceutical company, at Two Ledgemont Center in ... Richards , president, and Brian Cohen , senior vice ... building at 95 Hayden Ave. Photo - ...
(Date:1/22/2015)... / Rootstown, OH (PRWEB) January 22, 2015 ... platform, announced today that it has received AOAC-PTM Certifications for ... O1O3, O111, O121, and O145; collectively referred to as STEC ... O157, at 1 colony forming unit (cfu) per 325 g ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Controlled Substance ... Alliance, which helps companies check the legal requirements around ... expand to China. , As their international operations ... globally adopting software solutions built as a result of ...
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, Inc., ... Inc. (NASDAQ: SQNM ), the leading ... for next generation noninvasive prenatal tests (NIPT). Through ... technology, called Mantis™, to advance analysis of clinically-relevant ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... BMRN ) today announced that Jean-Jacques,Bienaime, Chief Executive ... 3rd Annual Citi Biotech Day in New York City ... Interested parties may access a live audio webcast of ... website, http://www.BMRN.com .,A replay of the call will ...
... development milestone payment to InterMune - ... to lead ITMN-191 program in Phase 2 -, BRISBANE, ... announced that InterMune has earned a $15 million,development milestone under ... NS3 protease inhibitor compound ITMN-191,(referred to as R7227 at Roche), ...
... ALTO, Calif., Sept. 2 CV Therapeutics,Inc. (Nasdaq: ... has enrolled the first,patient in a Phase 1 ... potential,treatment of cardiometabolic diseases. The U.S. Food and ... for CVT-3619, a partial A1 adenosine receptor agonist., ...
Cached Biology Technology:BioMarin to Present at the Citi Biotech Day 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 2InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 3InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche 4CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 2CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases 3
... Agencourts cDNA sequencing and finishing services ... Agencourt can perform large-scale 5' screening ... finishing. Our considerable experience with large-scale ... make Agencourt an ideal cDNA outsourcing ...
Shotgun library construction and high-throughput DNA sequencing of microbial genomes, BACs, adenoviruses, phosmids and cosmids. LIMS tracking utilizing Geospiza's Finch system....
... to human XAB2 (amino terminus) XAB2 ... its interaction with XPA. Immunoprecipitation experiments have ... interacts with the transcription-coupled repair-specific proteins CSA ... polymerase II. Microinjection experiments with XAB2 antibodies ...
...
Biology Products: